Sildenafil (Generic) vs Alprostadil (Caverject/MUSE): Side-Effect Profile Head-to-Head

How Each Drug Works, and Why the Route Determines the Side Effects

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in vascular smooth muscle. Because PDE5 is expressed throughout the body, in penile tissue, pulmonary vasculature, retinal photoreceptors, and systemic arterioles, oral sildenafil produces effects well beyond the pelvis. FDA prescribing information for sildenafil confirms PDE5 expression in retinal and pulmonary tissue as the mechanistic basis for visual and hemodynamic side effects. [1]

Alprostadil is synthetic prostaglandin E1 (PGE1). It binds EP receptors directly on cavernosal smooth muscle, raising intracellular cAMP and triggering erection independent of nitric oxide. Research published in NEJM by Linet et al. (1996, N=296) showed ~70% of men with ED refractory to other treatments responded to intracavernosal alprostadil. [2] Because the drug is delivered locally, either by injection into the corpus cavernosum (Caverject) or as a urethral pellet (MUSE), systemic absorption is limited, but local tissue reactions dominate the side-effect picture.

Why Route of Administration Is the Key Variable

The oral route of sildenafil guarantees first-pass hepatic metabolism and full systemic distribution via CYP3A4 and CYP2C9 pathways. The FDA label notes that the mean plasma Cmax after 100 mg oral sildenafil is approximately 440 ng/mL, sufficient to produce measurable reductions in supine blood pressure. [1] That systemic exposure explains the class-wide vascular side effects.

Caverject's intracavernosal injection achieves high local concentrations but rapid venous and lymphatic absorption limits circulating alprostadil levels. According to the Caverject FDA label, less than 1% of the injected dose is detectable in peripheral venous blood 30 minutes post-injection, which is why systemic prostaglandin effects are uncommon. [3] MUSE (medicated urethral system for erection) delivers alprostadil transurethally; absorption is higher than injection but still largely regional.

Sildenafil Side-Effect Profile: Systemic, Dose-Dependent, and Usually Mild

The landmark Goldstein et al. Trial (NEJM 1998, N=532) established the core sildenafil side-effect profile in a randomized, double-blind, placebo-controlled design. Goldstein et al. Reported headache in 16%, flushing in 10%, dyspepsia in 7%, and abnormal vision (color tinge, blurred vision) in 3% of men on sildenafil 50 to 100 mg vs. Rates of 4%, 1%, 2%, and 0% respectively on placebo. [4] These are dose-dependent, they increase moving from 25 mg through 50 mg to 100 mg.

Cardiovascular and Hemodynamic Effects

Sildenafil lowers mean arterial pressure by roughly 8 to 10 mmHg at the 100 mg dose. That effect is pharmacologically modest in healthy men but becomes clinically significant in three scenarios: concurrent nitrate use, severe aortic stenosis, and autonomic neuropathy. The FDA label carries a black-box contraindication against any form of nitrate co-administration because the combination can produce profound, potentially fatal hypotension. [1]

Alpha-blocker co-administration (e.g., tamsulosin for benign prostatic hyperplasia) also warrants caution. A 2002 pharmacodynamic study published in the Journal of Urology found that sildenafil 100 mg combined with doxazosin 4 mg produced symptomatic hypotension in 4 of 24 subjects. [5] Dose-spacing by at least 4 hours is the standard clinical mitigation.

Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare but serious concern. The FDA issued a labeling update in 2005 requiring a warning about NAION after postmarketing reports; however, a causal relationship was not definitively established because many affected men had pre-existing vascular risk factors. [1]

Sildenafil Hearing and Other Sensory Effects

Sudden sensorineural hearing loss has been reported with all PDE5 inhibitors. A 2007 case series and FDA safety review identified 29 postmarketing reports of sudden hearing loss associated with sildenafil; the FDA updated labeling accordingly, though absolute incidence remains unknown. [6] Patients should be advised to stop sildenafil immediately if sudden hearing or vision loss occurs.

Back Pain and Myalgia

Back pain and myalgia are more commonly associated with tadalafil than sildenafil. A comparative review in BJU International (2005) found back pain rates of ~6% for tadalafil 20 mg vs. 1 to 2% for sildenafil 50 to 100 mg, attributed to PDE11 inhibition unique to tadalafil. [7] Sildenafil's myalgia rate is low enough that it is not listed separately from placebo in most trial summaries.

Alprostadil Side-Effect Profile: Local, Predictable, and Technique-Dependent

Alprostadil's side effects cluster around the delivery site. Pain is the dominant complaint. Priapism is the most serious risk. Neither is systemic in the way sildenafil's effects are.

Penile Pain: The Most Frequent Complaint

The FDA label for Caverject Impulse (alprostadil intracavernosal injection) lists penile pain in approximately 37% of men during clinical trials at effective doses, making it the single most common adverse event. [3] The pain is typically mild-to-moderate, occurs during erection, and diminishes with continued use as patients adapt to the injection. Linet et al. (NEJM 1996) documented penile pain in 50% of men during dose-titration but noted that it rarely caused discontinuation at home-use doses. [2]

MUSE produces a similar but slightly lower pain rate. The MUSE key trial (Padma-Nathan et al., NEJM 1997, N=1,511) reported urethral burning in 36% of men and minor urethral bleeding in 5% of men using the 1000 mcg dose. [8] Partner vaginal burning was reported in 5.8% of female partners, a side effect absent from the sildenafil literature entirely.

Priapism and Prolonged Erection

Prolonged erection (more than 4 hours) is the most clinically urgent adverse event with alprostadil. The Caverject FDA label reports prolonged erection in approximately 4% and priapism in approximately 1% of men in clinical studies. [3] Patients must be instructed to seek emergency treatment immediately if erection persists beyond 4 hours, because ischemic priapism beyond 6 hours causes permanent cavernosal smooth-muscle necrosis. American Urological Association (AUA) guidelines on priapism state that "ischemic priapism lasting more than 4 hours is a urological emergency requiring prompt intervention to prevent irreversible erectile dysfunction." [9]

Sildenafil's priapism risk is substantially lower. The drug requires sexual stimulation and a functional nitric oxide axis, it does not produce erections by direct smooth-muscle activation. Published postmarketing surveillance data estimate sildenafil-associated priapism at fewer than 0.1 cases per 1,000 patient-years. [10]

Penile Fibrosis and Long-Term Injection Risk

Repeated intracavernosal injections carry a long-term risk that oral tablets do not: corporal fibrosis. The Caverject labeling notes penile fibrosis or Peyronie's disease-like plaque in approximately 3% of men in long-term studies, rising with injection frequency and technique errors. [3] Proper injection technique, alternating sides, using a 27-to-30-gauge needle, applying pressure for 5 minutes, reduces but does not eliminate this risk.

A long-term follow-up study published in the Journal of Urology (Coombs et al., 2012) found that after 3 years of regular alprostadil injections, 7.8% of men developed palpable plaques on penile examination. [11] That figure rises with higher doses and more frequent use.

Efficacy Side by Side: What the Trials Actually Show

Side effects matter less if a drug does not work. Efficacy context frames the clinical trade-off.

Sildenafil Efficacy Data

Goldstein et al. (NEJM 1998) enrolled 532 men with ED of broad etiology. At 100 mg, 69% of sildenafil attempts resulted in successful intercourse vs. 22% on placebo, a 47-percentage-point absolute difference, P<0.001. [4] The International Index of Erectile Function (IIEF) erectile function domain score improved by a mean of 7.0 points vs. 1.0 on placebo. Efficacy is reduced in severe arterial disease and post-radical prostatectomy with cavernous nerve injury.

Alprostadil Efficacy Data

Linet et al. (NEJM 1996, N=296) reported that 87% of men at home achieved at least one successful erection with intracavernosal alprostadil during the 6-month study period, with a per-injection response rate of approximately 70%. [2] MUSE is modestly less effective: Padma-Nathan et al. (NEJM 1997) reported successful intercourse in 64.9% of MUSE attempts vs. 18.6% placebo, across the full dose range. [8]

Who Responds to Alprostadil When Sildenafil Fails

Alprostadil's mechanism bypasses the nitric oxide pathway entirely, which is why it retains efficacy in populations where sildenafil does not. A 2001 European Urology review of post-prostatectomy ED found that intracavernosal alprostadil produced satisfactory erections in 68% of nerve-sparing and 46% of non-nerve-sparing prostatectomy patients. [12] Sildenafil efficacy in non-nerve-sparing post-prostatectomy patients is consistently under 15% in published series. Diabetic men with autonomic neuropathy similarly show higher alprostadil response rates than PDE5 inhibitor response rates when arterial disease is severe.

Contraindications and Drug Interactions: Where the Profiles Diverge Most

The contraindication profiles are almost completely non-overlapping, which is clinically useful, a man contraindicated for sildenafil is often a candidate for alprostadil, and vice versa.

Sildenafil Contraindications

Absolute contraindications: any organic nitrate or nitric oxide donor (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrate poppers), riociguat (another cGMP pathway drug), and known hypersensitivity to sildenafil. The FDA label specifies that nitrates are contraindicated regardless of route of administration or frequency of use. [1] Relative contraindications include recent stroke or myocardial infarction (within 6 months), severe hepatic impairment (Child-Pugh C), and resting hypotension (systolic <90 mmHg). Strong CYP3A4 inhibitors, ketoconazole, ritonavir, clarithromycin, markedly increase sildenafil plasma levels and mandate dose reduction to 25 mg.

Alprostadil Contraindications

Alprostadil is contraindicated in men with conditions predisposing to priapism: sickle-cell anemia, sickle-cell trait, thrombocythemia, polycythemia, multiple myeloma, and leukemia. The Caverject label also contraindicates use in men with penile implants or with anatomical deformation of the penis (Peyronie's disease with significant curvature) severe enough to preclude safe injection. [3] Unlike sildenafil, alprostadil has no nitrate interaction and no CYP3A4 interaction of clinical significance.

Anticoagulant therapy increases injection-site bruising and hematoma risk but is not an absolute contraindication, rather, the injection technique must be especially precise, and pressure held for a minimum of 5 minutes.

Patient Selection: Matching the Drug to the Clinical Scenario

The right drug depends on three factors: disease etiology, comorbidities, and patient preference regarding route.

First-Line vs. Second-Line Positioning

The 2018 American Urological Association (AUA) Guidelines on Erectile Dysfunction categorize oral PDE5 inhibitors as first-line therapy for most men with ED, with intracavernosal injections as second-line after PDE5 inhibitor failure or contraindication. [13] That guideline reflects the favorable oral tolerability, broad availability, and non-invasive nature of sildenafil. Alprostadil injection requires in-office training before home use, a meaningful friction point that sildenafil does not carry.

Scenarios Where Alprostadil Is the Better Choice

Post-radical prostatectomy with non-nerve-sparing technique, severe penile arterial insufficiency, and documented PDE5 inhibitor non-response after three adequate attempts at the highest tolerated dose all support moving to alprostadil. A 1999 study in Urology (Raina et al.) also found that early use of intracavernosal alprostadil after prostatectomy, "penile rehabilitation", improved recovery of spontaneous erections at 18 months vs. No treatment. [14]

Men on nitrates for coronary artery disease represent the most clear-cut scenario: sildenafil is absolutely contraindicated and alprostadil is the only approved pharmacotherapy option. Those men may also consider penile prosthesis after counseling.

Scenarios Where Sildenafil Remains Preferable

Psychogenic or mixed-etiology ED in otherwise healthy men. Younger patients with performance anxiety. Men who require spontaneity (sildenafil onset is 30 to 60 minutes; alprostadil injection onset is 5 to 20 minutes but requires the injection ritual). Men with needle phobia. A validated patient-preference study published in BJU International (Porst et al., 2007, N=1,112) found that 87.5% of men who had tried both oral PDE5 inhibitors and intracavernosal injection preferred the oral route. [15]

Dosing Reference and Side-Effect Frequency Table

| Parameter | Sildenafil Generic | Alprostadil Caverject | Alprostadil MUSE | |---|---|---|---| | Dose range | 25, 50, 100 mg oral | 2.5 to 40 mcg intracavernosal | 125 to 1000 mcg intraurethral | | Onset | 30 to 60 min | 5 to 20 min | 5 to 10 min | | Duration | 4 to 6 hours | 1 to 2 hours | 30 to 60 min | | Headache | 16% (50 mg) [4] | <1% | <1% | | Flushing | 10% (50 mg) [4] | <1% | <1% | | Visual changes | 3% [4] | none reported | none reported | | Penile pain | <1% | ~37% [3] | ~36% [8] | | Priapism | <0.1% [10] | ~1% [3] | <1% [8] | | Penile fibrosis | not applicable | ~3% (long-term) [11] | not applicable | | Hypotension risk | yes (especially with nitrates) | minimal | minimal | | Systemic interaction risk | CYP3A4, nitrates | negligible | negligible |

Combining Sildenafil and Alprostadil: Is It Done?

Some urologists use combination regimens in severe refractory ED. A 2003 study in the Journal of Urology (McMahon et al., N=82) found that combining low-dose intracavernosal alprostadil with sildenafil in men who had failed monotherapy with each drug produced satisfactory erections in 73% of attempts, with additive but manageable side-effect rates. [16] Priapism risk increases with combination use, and dosing must be titrated conservatively. This approach sits outside standard first- or second-line care and requires specialist supervision.

The FDA has not approved any fixed combination product; off-label use must be documented carefully, and patients need written instructions specifying the maximum total dose and the emergency threshold for seeking priapism treatment. [3]

Monitoring and Follow-Up Considerations

For Sildenafil Patients

Baseline blood pressure measurement before prescribing is recommended. The Princeton Consensus (Third Princeton Consensus Panel, 2012) stratified cardiovascular risk before PDE5 inhibitor prescribing, classifying men as low, intermediate, or high risk and recommending stress testing before PDE5 inhibitor use in the intermediate group. [17] Follow up at 4 to 8 weeks to confirm dose adequacy and screen for side effects.

For Alprostadil Patients

In-office dose titration is mandatory before home use. The Caverject prescribing information specifies that the first injection must be performed by a healthcare provider with monitoring for prolonged erection, hypotension, and vasovagal response for at least 30 minutes. [3] Patients should return every 3 months for penile examination to detect early fibrosis or plaque formation. Injection frequency should not exceed once daily or three times per week.

A 2006 consensus statement from the European Association of Urology recommended that intracavernosal therapy patients receive periodic penile ultrasound if fibrosis symptoms develop, and that dose reduction be attempted before abandoning the therapy. [18]